Moleculin Biotech, Inc. is preclinical and clinical-stage pharmaceutical company focused on the development of game-changing anti-cancer drug candidates, many of which are based on discoveries made at M.D. Anderson Cancer Center. Each of our projects represents a breakthrough discovery and a highly disruptive technology.

Home » Investors » All SEC Filings »

All SEC Filings

Filing Type:

Year:

Date	Form	Description	Pages
06/27/17	8-K	Current report filing Documents EX-99.1 EX-99.2	8
06/13/17	8-K	Current report filing Documents EX-99.1	5
05/31/17	8-K	Current report filing Documents EX-10.1	18
05/23/17	DEFA14A	Additional definitive proxy soliciting materials and Rule 14(a)(12) material	7
05/23/17	8-K	Current report filing Documents EX-99.1	8
05/19/17	8-K	Current report filing	3
05/16/17	8-K	Current report filing Documents EX-99.1	9
05/12/17	4	Statement of changes in beneficial ownership of securities	2
05/12/17	10-Q	Quarterly report pursuant to Section 13 or 15(d) Documents EX-31.1 EX-31.2 EX-32.1 EX-32.2	35
05/05/17	4	Statement of changes in beneficial ownership of securities	2

5
6
7
8
9
10
11
12
13
14

All SEC Filings

SEC Filings

Quick Links